Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review

Abstract

Background COVID-19 caused by SARS-CoV-2 was declared as a global pandemic by the WHO. Famotidine is a histamine-2 (H2) receptor antagonist which blocks the H2 receptors in the parietal cells, decreasing gastric acid secretion. Our review aims to study all the available scientific evidence on famotidine research outcomes systematically to introspect its clinical efficacy and probable mechanisms and clinical efficacy against SARS-CoV-2.

Methodology An electronic search of PubMed, Scopus and Google Scholar was performed using MeSH terms “SARS CoV-2” OR “COVID-19” AND“FAMOTIDINE”. Relevant informationwas extracted from studies reporting the efficacy of famotidine in COVID-19.

Results We found a total of 32 studies, out of which only 14 were relevant and were included in our review.Molecular computational studies showed that famotidine selectively acts on viral replication proteases papain-like protease (PLpro) and 3-chymotrypsin-like protease (3CLpro). Additionally, it acts via inverse-agonism on the H2 receptors present in neutrophils and eosinophils which leads to inhibition of cytokine release. Clinical study findings have pointed toward significant improvements in COVID-19 patient-reported symptoms in non-hospitalized patients and reduction in intubation or death in critically ill patients associated with the usage of famotidine. However,in one of the studies,famotidine has failed to show any significant benefit in reducing mortality due to COVID-19.

Conclusion Famotidine has the potential to answer the ongoing global challenge owing to its selective action on viral replication. Additionally, clinical findings in COVID-19 patients support its efficacy to reduce clinical symptoms of COVID-19.We suggest that further optimally powered randomized clinical trials should be carried out to come up with definitive conclusions.

Key words

Famotidine - Infectious disease - SARS-CoV-2 - COVID-19 - drug repurposing

Publication History

Received: 24 November 2020

Accepted: 17 February 2021

Article published online:
23 March 2021

• References

• 1 Johns Hopkins University. Coronavirus Resource Center. Available from: https://coronavirus.jhu.edu/map.html (accessed on February12, 2021)
• 2 Saxena A. Drug targets for COVID-19 therapeutics: Ongoing global efforts. J Biosci 2020; 45: 87 doi: 10.1007/s12038-020-00067-w
• 3 Guy RK, DiPaola RS, Romanelli F. et al. Rapid repurposing of drugs for COVID-19. Science 2020; 368: 829-830 DOI: 10.1126/science.abb9332.
• 4 Elmezayen AD, Al-Obaidi A, Şahin AT. et al. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J Biomol Struct Dyn 2020; 1-13 DOI: 10.1080/07391102.2020.1758791.
• 5 Lowe D.. Famotidine, Histamine, and the Coronavirus. Science Translational Medicine. 2020 Available from https://blogs.sciencemag.org/pipeline/archives/2020 (accessed on February12, 2021)
• 6 Moher D, Liberati A, Tetzlaff J. et al. The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097
• 7 Higgins JPT, Green S. (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0 The Cochrane Collaboration. 2011 http://www.handbook.cochrane.org (accessed on February12, 2021)
• 8 Ortega JT, Serrano ML, Jastrzebska B. Class AG Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV-2: An In Silico Analysis. Biomolecules 2020; 10: E954 doi:10.3390/biom10060954
• 9 Sen Gupta PS, Biswal S, Singha D. et al. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2. J Biomol Struct Dyn 2020; 1-7 DOI: 10.1080/07391102.2020.1784795.
• 10 Wu C, Liu Y, Yang Y. et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10: 766-788 DOI: 10.1016/j.apsb.2020.02.008.
• 11 Singh VP, El-Kurdi B, Rood C. What underlies the benefit of famotidine formulations used during COVID-19?. Gastroenterology. 2020: S0016-5085 (20)35020-4 DOI: 10.1053/j.gastro.2020.07.051
• 12 Malone RW, Tisdall P, Fremont-Smith P. et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Res Sq [Preprint]. 2020: rs.3.rs-30934 DOI: 10.21203/rs.3.rs-30934/v2
• 13 Anson BJ, Chapman ME, Lendy EK. et al. Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs. Res Sq [Preprint] 2020; rs.3.rs-26344 DOI: 10.21203/rs.3.rs26344/v1.
• 14 Janowitz T, Gablenz E, Pattinson D. et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut2020; gutjnl-2020-321852.. DOI: 10.1136/gutjnl-2020-321852
• 15 Freedberg DE, Conigliaro J, Wang TC. et al. Famotidine Research Group. Famotidine Use Is Associatedroved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology 2020; 159: 1129-1131.e3 DOI: 10.1053/j.gastro.2020.05.053.
• 16 Mather JF, Seip RL, McKay RG. Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19. Am J Gastroenterol 2020; 115: 1617-1623 doi: 10.14309/ajg.0000000000000832
• 17 Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol 2020; 115: 1707-1715 doi: 10.14309/ajg.0000000000000798
• 18 Hogan Ii RB, Hogan Iii RB, Cannon T. et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. PulmPharmacolTher 2020; 63: 101942 DOI: 10.1016/j.pupt.2020.101942.
• 19 Yeramaneni S, Doshi P, Sands K. et al. Famotidine use is not associated with 30-day mortality: a coarsened exact match study in 7158 hospitalized patients with coronavirus disease 2019 from a large healthcare system. Gastroenterology 2021; 160: 9e3. DOI: 10.1053/j.gastro.2020.10.011.
• 20 Zhou J, Wang X, Lee S. et al. Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study. Gut2020:gutjnl-2020-323668. DOI: 10.1136/gutjnl-2020-323668
• 21 Cheung KS, Hung IF, Leung WK. Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study. Gastroenterology. 2020: S0016-5085 (20)34940-4 DOI: 10.1053/j.gastro.2020.05.098
• 22 Moharana AK, Bhattacharya SK, Mediratta PK. et al. Possible role of histamine receptors in the central regulation of immune responses. Indian J PhysiolPharmacol 2000; 44: 153-160
• 23 Skidgel RA, Kaplan AP, Erdös EG.. Histamine, Bradykinin, and Their Antagonists. In: Brunton LL, Chabner BA, Knollmann BC. Eds Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e. McGraw-Hill (accessed on February 12, 2021);
• 24 Smolinska S, Jutel M, Crameri R. et al. Histamine and gut mucosal immune regulation. Allergy 2014; 69: 273-281 DOI: 10.1111/all.12330.
• 25 Ghanouni P, Gryczynski Z, Steenhuis JJ. et al. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 2001; 276: 24433-24436 DOI: 10.1074/jbc.C100162200.
• 26 Reher TM, Brunskole I, Neumann D. et al. Evidence for ligand-specific conformations of the histamine H(2)-receptor in human eosinophils and neutrophils.Biochem Pharmacol 2012; 84: 1174-1185
• 27 Alonso N, Monczor F, Echeverría E. et al. Signal transduction mechanism of biased ligands at histamine H2 receptors. Biochem J 2014; 459: 117-126 DOI: 10.1042/BJ20131226.
• 28 Alonso N, Zappia CD, Cabrera M. et al. Physiological implications of biased signalling at histamine H2 receptors. Front Pharmacol 2015; 6: 45
• 29 Soll AH, Wollin A. Histamine and cyclic AMP in isolated canine parietal cells. Am J Physiol 1979; 237: E444-50 doi: 10.1152/ajpendo.1979.237.5.E444
• 30 Apolloni S, Fabbrizio P, Parisi C. et al. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Mol Neurobiol 2016; 53: 518-531 DOI: 10.1007/s12035-014-9019-8.
• 31 Colucci R, Fleming JV, Xavier R. et al. L-histidine decarboxylase decreases its own transcription through downregulation of ERK activity. Am J PhysiolGastrointest Liver Physiol 2001; 28: G1081-G1091 DOI: 10.1152/ajpgi.2001.281.4.G1081.
• 32 ACCC Branco, FSY Yoshikawa, Pietrobon AJ. et al. Role of Histamine in Modulating the Immune Response and Inflammation. Mediators Inflamm 2018; 2018:9524075.2018 DOI: 10.1152/jappl.58.4.1092.
• 33 Rada B, Boudreau HE, Park JJ, Leto TL. . Histamine stimulates hydrogen peroxide production by bronchial epithelial cells via histamine H1 receptor and dual oxidase. Am J Respir Cell Mol Bio 2014; 50 125–134. DOI: 10.1165/rcmb.2013-0254OC.
• 34 Walkenstein MD, Peterson BT, Gerber JE. et al. Histamine-induced pulmonary edema distal to pulmonary arterial occlusion. J Appl Physiol 1985; 58: 1092-1098 DOI: 10.1152/jappl.58.4.1092.
• 35 Sirois J, Ménard G, Moses AS. et al. Importance of histamine in the cytokine network in the lung through H2 and H3 receptors: stimulation of IL-10 production. J Immunol 2000; 164: 2964-2970 DOI: 10.4049/jimmunol.164.6.2964.
• 36 Vannier E, Miller LC, Dinarello CA. Histamine suppresses gene expression and synthesis of tumor necrosis factor-alpha via histamine H2 receptors. J Exp Med 1991; 174: 281-284 doi:10.1084/jem.174.1.281
• 37 Azuma Y, Shinohara M, Wang PL. et al. Histamine inhibits chemotaxis, phagocytosis, superoxide anion production, and the production of TNF alpha and IL-12 by macrophages via H2-receptors. Int Immunopharmacol 2001; 1: 1867-1875 DOI: 10.1016/s1567-5769(01)00112-6.
• 38 Wang Z, Yang B, Li Q. et al. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71: 769-777 DOI: 10.1093/cid/ciaa272.
• 39 Jutel M, Watanabe T, Akdis M. et al. Immune regulation by histamine. CurrOpin Immunol 2002; 14: 735-740 DOI: 10.1016/s0952-7915(02)00395-3.
• 40 Lichtenstein LM, Gillespie E. The effects of the H1 and H2 antihistamines on “allergic” histamine release and its inhibition by histamine. J Pharmacol Exp Ther 1975; 192: 441-450
• 41 Bourinbaiar AS, Fruhstorfer EC. The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. Life Sci 1996; 59: PL 365-370 doi: 10.1016/s0024-3205(96)00553-x
• 42 Alonso N, Zappia CD, Cabrera M. et al. Physiological implications of biased signaling at histamine H2 receptors. Front Pharmacol 2015; 6: 45. DOI: 10.3389/fphar.2015.00045.
• 43 Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis.. Brain BehavImmun 2020; 87: 59-73 doi:10.1016/j.bbi.2020.04.046
• 44 Meiler F, Zumkehr J, Klunker S. et al. In vivo switch to Il-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205: 2887-2898 DOI: 10.1084/jem.20080193.
• 45 O'Mahony L, Akdis M, Akdis CA. Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol 2011; 128: 1153-6112 doi:10.1016/j.jaci.2011.06.051
• 46 Bertaccini G, Coruzzi G, Poli E. et al. Pharmacology of the novel H2 antagonist famotidine: in vitro studies. Agents Actions 1986; 19: 180-187 DOI: 10.1007/BF01966204.
• 47 Infectious Disease Society of America. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (accessed on February 12, 2021)
• 48 ClinicalTrials.gov. Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT04504240 (accessed on February 12, 2021)
• 49 Eom CS, Jeon CY, Lim JW. et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310-319 DOI: 10.1503/cmaj.092129.